BIO-TECHNE Corp Stock Nasdaq
Equities
US8783771004
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Financials (USD)
Sales 2024 * | 1.16B | Sales 2025 * | 1.25B | Capitalization | 11.32B |
---|---|---|---|---|---|
Net income 2024 * | 180M | Net income 2025 * | 228M | EV / Sales 2024 * | 9.91 x |
Net Debt 2024 * | 166M | Net cash position 2025 * | 85.4M | EV / Sales 2025 * | 9 x |
P/E ratio 2024 * |
64.2
x | P/E ratio 2025 * |
51.3
x | Employees | - |
Yield 2024 * |
0.45% | Yield 2025 * |
0.45% | Free-Float | 99.03% |
Latest transcript on BIO-TECHNE Corp
Managers | Title | Age | Since |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 18-04-29 |
James Hippel
DFI | Director of Finance/CFO | 53 | 14-03-31 |
Matthew McManus
COO | Chief Operating Officer | 55 | Jan. 07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 02-12-31 | |
Randolph Steer
BRD | Director/Board Member | 74 | 89-12-31 |
Joseph Keegan
BRD | Director/Board Member | 71 | 17-10-25 |
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.1B | |
-8.62% | 38.76B | |
+26.95% | 31.24B | |
+10.74% | 25.9B | |
-13.50% | 25.8B | |
+44.87% | 14.06B | |
+34.36% | 13.12B | |
-12.61% | 10.68B | |
-8.23% | 9.12B |